# Nanoviricides, Inc.: overview NNVC · NYSE · CIK 1379006 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/nnvc.md) · [Financials](/companies/nnvc/financials.md) · [Filings](/companies/nnvc/filings.md) · [Insiders](/companies/nnvc/insiders.md) Latest reported revenue: [$0](/filings/0001104659-26-111390.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001104659-26-111390). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001410578-24-001991.md) | [0.0 d](/filings/0001410578-25-000140.md) | [0.0 d](/filings/0001410578-25-001336.md) | [0.0 d](/filings/0001104659-25-094527.md) | [0.0](/filings/0001104659-25-112608.md) | [0.0 d](/filings/0001104659-26-016476.md) | [0.0 d](/filings/0001104659-26-061499.md) | [0.0 d](/filings/0001104659-26-111390.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.23)](/filings/0001104659-25-112608.md) | [(0.14)](/filings/0001104659-26-016476.md) | [(0.14)](/filings/0001104659-26-061499.md) | not reported | [(0.10)](/filings/0001104659-25-112608.md) | [(0.11)](/filings/0001104659-26-016476.md) | [(0.09)](/filings/0001104659-26-061499.md) | not reported | | Free cash flow | $k | [(2,642)](/filings/0001104659-25-112608.md) | [(2,191) d](/filings/0001104659-26-016476.md) | [(1,991) d](/filings/0001104659-26-061499.md) | [(1,712) d](/filings/0001104659-26-111390.md) | [(1,678)](/filings/0001104659-25-112608.md) | [(2,050) d](/filings/0001104659-26-016476.md) | [(1,931) d](/filings/0001104659-26-061499.md) | [(2,122) d](/filings/0001104659-26-111390.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [0.0](/filings/0001410578-23-002146.md) | [0.0](/filings/0001410578-24-001650.md) | [0.0](/filings/0001104659-25-094527.md) | [0.0](/filings/0001104659-26-111390.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.70)](/filings/0001410578-23-002146.md) | [(0.74)](/filings/0001410578-24-001650.md) | [(0.70)](/filings/0001104659-25-094527.md) | [(0.63)](/filings/0001104659-26-111390.md) | [(0.41)](/filings/0001104659-26-111390.md) | | Free cash flow | $k | [(6,216)](/filings/0001410578-23-002146.md) | [(5,822)](/filings/0001410578-24-001650.md) | [(6,472)](/filings/0001104659-25-094527.md) | [(8,536)](/filings/0001104659-26-111390.md) | [(7,780)](/filings/0001104659-26-111390.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nnvc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.3m | 919,313 | | Added +407,836 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $298.2k | 216,022 | | Reduced −9,359 | | [Connective Capital Management, LLC](/funds/1543568.md) | 2026-06-30 | $255.6k | 185,217 | | New +185,217 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $219.1k | 158,753 | | Added +1 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $182.1k | 131,923 | | Added +41,863 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $177.5k | 128,600 | | Reduced −6,300 | | [Miller Financial Services LLC](/funds/2022893.md) | 2026-06-30 | $154.6k | 112,000 | | Added +7,000 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $137.1k | 99,331 | | Reduced −114,028 | | [Creative Planning](/funds/1540235.md) | 2026-06-30 | $119.7k | 86,761 | | New +86,761 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $100.7k | 73,000 | Call | Added +37,100 | ## Recent filings [All 509 filings](/companies/nnvc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 15:28 ET | [DEF 14A](/filings/0001104659-26-114606.md) | Proxy statement, period 2026-11-21 | 0001104659-26-114606 | | 2026-09-29 | 20:30 ET | [8-K](/filings/0001104659-26-111952.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-111952 | | 2026-09-28 | 20:30 ET | [10-K](/filings/0001104659-26-111390.md) | Annual report, period 2026-06-30 | 0001104659-26-111390 | | 2026-07-30 | 10:02 ET | [8-K](/filings/0001104659-26-088393.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-088393 | | 2026-07-17 | 20:45 ET | [8-K](/filings/0001104659-26-084668.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-084668 | | 2026-05-21 | 10:01 ET | [8-K](/filings/0001104659-26-064754.md) | 7.01 Regulation FD disclosure | 0001104659-26-064754 | | 2026-05-20 | 20:30 ET | [8-K](/filings/0001104659-26-064544.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-064544 | | 2026-05-15 | 00:37 ET | [10-Q](/filings/0001104659-26-061499.md) | Quarterly report, period 2026-03-31 | 0001104659-26-061499 | | 2026-02-17 | 21:30 ET | [10-Q](/filings/0001104659-26-016476.md) | Quarterly report, period 2025-12-31 | 0001104659-26-016476 | | 2025-11-26 | 21:30 ET | [8-K](/filings/0001104659-25-116457.md) | 5.07 Shareholder vote results | 0001104659-25-116457 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001104659-26-111390.md), filed Sep 28, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d1e6566c-bbf6-4f77-90dd-fc74a3f16585) ## About the filer - CIK: 1379006 - Tickers: NNVC - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.